Antimicrobial restrictions

Antimicrobial formulary

The Queensland Children’s Hospital (QCH) antimicrobial formulary is a core component of the Antimicrobial stewardship program.

It is the responsibility of the prescriber to obtain appropriate AMS code for restricted antimicrobials.

Use of a restricted antimicrobials at QCH can be authorised with a unique AMS Code by the Paediatric Infection Specialists/clinicians listed below

Dr Julia Clark
Dr Clare Nourse
Dr Sophie Wen
Dr Adam Irwin
Dr Vikram Vaska
Dr Angela Berkhout
QCH ID Fellow (only for LAM listed items – use outside the LAM requires an IPA signed off by an ID SMO)

QCH Antimicrobial Formulary

The QCH Antimicrobial formulary should be used in conjunction with the current Queensland Health List of Approved Medicines (LAM).

All other antimicrobials not listed or used for off label/ off license indications, require a CGOV Individual patient approval request submitted by the Treating Clinician and authorised by a Paediatric Infection Specialist prior to prescribing, supply or use.

Specific clinical scenarios involving antimicrobials that require authorisation by a Paediatric Infection Specialist, are listed in the CHQ-PROC-01036 Antimicrobial: Prescribing and Management (health.qld.gov.au).

For more information about Antimicrobial supply at QCH, please refer to CHQ-PROC-01036 Antimicrobial: Prescribing and Management (health.qld.gov.au) for guidance.

The QCH Antimicrobial formulary is divided into the following three categories:

Unrestricted (green)

Green Antimicrobials can be prescribed for a clinically appropriate indication and duration by all prescribers as per LAM criteria. Document the indication, dose and duration with each prescription/ order.

Restricted (amber)

Amber Antimicrobials can be prescribed for listed indications for specific time frame. However, approval is required for use outside these indications (and time frames).

Where use is outside these criteria, an AMS code is required, the Prescriber will contact the Paediatric Infection Specialist or ID Fellow on service who will consider the antimicrobial’s use and duration of therapy.

Please document:

The indication
Intended dose and duration of therapy or review date
The unique AMS Code and the name of the authorising Paediatric Infection specialist must be added to the antimicrobial order/prescription and the ieMR clinical note.

For SAS antimicrobials, the prescriber must also complete the following electronic approval requests to pharmacy and infectious diseases consultant on service:

Reserved (red)

Red Antimicrobials may only be prescribed for following authorisation by Paediatric Infection Specialist or ID Fellow on service through provision of a unique AMS Code.

Please document:

The indication
Intended dose and duration of therapy or review date
The unique AMS Code must be added to the antimicrobial order/prescription and the name of the authorising Paediatric Infection specialist to the ieMR clinical note.

For SAS antimicrobials, the prescriber must also complete the following electronic approval requests to pharmacy and infectious diseases consultant on service:

For more information about Antimicrobial supply at QCH, please refer to CHQ-PROC-01036 Antimicrobial: Prescribing and Management (health.qld.gov.au)

Search QCH Antimicrobial formulary (generic name)

Antibiotic	Colour code
Amoxicillin (oral/IV) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications: Pre-approved for first dose challenge, IDT or SPT and desensitisation by Paediatric Immunologist/Allergist. Clinically appropriate indications and duration as per Australian Therapeutic guidelines or CHQ Infection/AMS guidelines	Green
Amoxicillin / Clavulanic acid (oral) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications: Pre-approved for first dose challenge, IDT or SPT and desensitisation by Paediatric Immunologist/Allergist. Clinically appropriate indications and duration as per Australian Therapeutic guidelines or CHQ Infection/AMS guidelines	Green
Amphotericin B lozenges (oral) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications: Clinically appropriate indications and duration as per Australian Therapeutic guidelines or CHQ Infection/AMS guidelines	Green
Benzathine penicillin (IM) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications: Clinically appropriate indications and duration as per Australian Therapeutic guidelines or CHQ Infection/AMS guidelines	Green
Benzylpenicillin (IV) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications: Pre-approved for first dose challenge, IDT or SPT and desensitisation by Paediatric Immunologist/Allergist. Clinically appropriate indications and duration as per Australian Therapeutic guidelines or CHQ Infection/AMS guidelines	Green
Cefaclor (oral) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications: Pre-approved for first dose challenge, IDT or SPT and desensitisation by Paediatric Immunologist/Allergist. Clinically appropriate indications and duration as per Australian Therapeutic guidelines or CHQ Infection/AMS guidelines	Green
Cefalexin (oral) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications: Pre-approved for first dose challenge, IDT or SPT and desensitisation by Paediatric Immunologist/Allergist. Clinically appropriate indications and duration as per Australian Therapeutic guidelines or CHQ Infection/AMS guidelines	Green
Cefazolin (IV) (inpatient) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications: Pre-approved for first dose challenge, IDT or SPT and desensitisation by Paediatric Immunologist/Allergist. Clinically appropriate indications and duration as per Australian Therapeutic guidelines or CHQ Infection/AMS guidelines	Green
Chloramphenicol eyedrops (topical) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications: Clinically appropriate indications and duration as per Australian Therapeutic guidelines or CHQ Infection/AMS guidelines	Green
Clotrimazole (topical) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications: Clinically appropriate indications and duration as per Australian Therapeutic guidelines or CHQ Infection/AMS guidelines	Green
Dicloxacillin (IV/oral) Product discontinued January 2022. Approval required for all indications.	Red
Flucloxacillin (IV/oral) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications: Pre-approved for first dose challenge, IDT or SPT and desensitisation by Paediatric Immunologist/Allergist. Clinically appropriate indications and duration as per Australian Therapeutic guidelines or CHQ Infection/AMS guidelines	Green
Framycetin - Gramicidin - Dexamethasone (Sofradex / Otodex) Ear drops Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications: Clinically appropriate indications and duration as per Australian Therapeutic guidelines or CHQ Infection/AMS guidelines	Green
Metronidazole (oral/IV) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications: Pre-approved for first dose challenge, IDT or SPT and desensitisation by Paediatric Immunologist/Allergist. Clinically appropriate indications and duration as per Australian Therapeutic guidelines or CHQ Infection/AMS guidelines	Green
Miconazole (topical) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications: Clinically appropriate indications and duration as per Australian Therapeutic guidelines or CHQ Infection/AMS guidelines	Green
Nitrofurantoin (oral capsules) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications: Pre-approved for first dose challenge, IDT or SPT and desensitisation by Paediatric Immunologist/Allergist. Clinically appropriate indications and duration as per Australian Therapeutic guidelines or CHQ Infection/AMS guidelines	Green
Nystatin (oral/ topical) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications: Clinically appropriate indications and duration as per Australian Therapeutic guidelines or CHQ Infection/AMS guidelines	Green
Permethrin (topical) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications: Clinically appropriate indications and duration as per Australian Therapeutic guidelines or CHQ Infection/AMS guidelines	Green
Phenoxymethylpenicillin (oral) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications: Pre-approved for first dose challenge, IDT or SPT and desensitisation by Paediatric Immunologist/Allergist. Clinically appropriate indications and duration as per Australian Therapeutic guidelines or CHQ Infection/AMS guidelines	Green
Pyrantel (oral) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications: Pre-approved for first dose challenge, IDT or SPT and desensitisation by Paediatric Immunologist/Allergist. Clinically appropriate indications and duration as per Australian Therapeutic guidelines or CHQ Infection/AMS guidelines	Green
Roxithromycin (150mg oral tablets) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications: Pre-approved for first dose challenge, IDT or SPT and desensitisation by Paediatric Immunologist/Allergist. Clinically appropriate indications and duration as per Australian Therapeutic guidelines or CHQ Infection/AMS guidelines	Green
Tinidazole (oral) (SAS) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) · Custom Portal (health.gov.au approval required	Green
Trimethoprim (oral tablets) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications: Pre-approved for first dose challenge, IDT or SPT and desensitisation by Paediatric Immunologist/Allergist. Clinically appropriate indications and duration as per Australian Therapeutic guidelines or CHQ Infection/AMS guidelines	Green
Trimethoprim / Sulfamethoxazole (oral) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications: Pre-approved for first dose challenge, IDT or SPT and desensitisation by Paediatric Immunologist/Allergist. Clinically appropriate indications and duration as per Australian Therapeutic guidelines or CHQ Infection/AMS guidelines	Green
Aciclovir (eye ointment) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications: Upon advice of Ophthalmologist	Amber
Aciclovir (topical cream) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications: Upon advice of Haematologist/Oncologist	Amber
Aciclovir (IV/oral) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Pre-approved for first dose challenge by Paediatric Immunologist/Allergist. Ongoing use/ desensitisation – ID approval required. IV Aciclovir not suitable for IDT or SPT due to alkaline pH Herpes simplex encephalitis (IV only - 72 hours) Cutaneous or mucosal herpes simplex in immunosuppressed patients (72 hours) Disseminated herpes zoster in immunocompromised patients (72 hours) Varicella zoster encephalitis or pneumonia in all patients (IV only - 72 hours) Ophthalmic herpes zoster (72 hours)	Amber
Albendazole (oral) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications: Pre-approved for first dose challenge, IDT or SPT by Paediatric Immunologist/Allergist. For prophylaxis against Snail and Slug Ingestion (Angiostrongylus cantonensis infection/ rat lung worm) As per QH LAM criteria.	Amber
Amoxicillin/Clavulanate (IV) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Pre-approved for first dose challenge, IDT or SPT by Paediatric Immunologist/Allergist. Ongoing use/ desensitisation – ID approval required. Retropharyngeal abscess (24 hours) Animal bites – see guideline (24 hours) Facial cellulitis of dental origin (24 hours) Uncomplicated appendicitis (72 hours) Complicated appendicitis, peritonitis, NEC (96 hours)	Amber
Amoxicillin, Clarithromycin and Esomeprazole (Triple therapy) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Eradication of proven Helicobacter pylori for 7 to 14 days under care of a Gastroenterologist according to the Australian Therapeutic guidelines (Antibiotics).	Amber
Liposomal Amphotericin B (IV) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Pre-approved for first dose challenge, IDT or SPT by Paediatric Immunologist/Allergist. Ongoing use/ desensitisation – ID approval required. Prolonged febrile neutropenia (24 hours then ID review required) Antifungal prophylaxis in oncology inpatients– see guideline (72 hours then ID review required) Liver transplant surgical prophylaxis – see guideline (5 days)	Amber
Azithromycin (IV) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Pre-approved for first dose challenge, IDT or SPT by Paediatric Immunologist/Allergist. Ongoing use/ desensitisation – ID approval required. Severe community acquired pneumonia (PICU) (24 hours then ID review required) Severe acute B.pertussis infection (PICU) (24 hours then ID review required)	Amber
Azithromycin (oral) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Pre-approved for first dose challenge by Paediatric Immunologist/Allergist. Ongoing use/ desensitisation – ID approval required. Patients with Cystic fibrosis– see criteria in guideline Patients with Non CF bronchiectasis – see criteria in guideline Severe community acquired pneumonia (PICU) (24 hours then ID review required) Severe acute B.pertussis infection (PICU) (24 hours then ID review required) Sexually transmitted disease (STD) prophylaxis – see guideline (single dose)	Amber
Cefazolin (with preservative) eyedrops Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Upon advice from Ophthalmology for Acute management of Open Globe Injuries, keratitis, endophthalmitis (health.qld.gov.au)	Amber
Cefazolin (IV) (HITH) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications for specific timeframes (for ongoing use, AMS code required): HITH - Patient with Non CF bronchiectasis as per guideline (Up to 14 days, 1^st dose as inpatient) According to HITH ED pathway (1^st dose in ED, then up to 48 hours on HITH, then ID review and AMS code required) for the following indications: Community acquired pneumonia (not tolerating oral therapy) Cellulitis Lymphadenitis Pre-septal/peri-orbital cellulitis	Amber
Cefepime (IV) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Pre-approved for first dose challenge by Paediatric Immunologist/Allergist. Ongoing use/ desensitisation – ID approval required. Upon advice from Renal consultant according to CHQ Paediatric Peritoneal Dialysis Peritonitis Clinical Pathway (72 hours then ID review required)	Amber
Cefotaxime (IV) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Pre-approved for first dose challenge by Paediatric Immunologist/Allergist. Ongoing use/ desensitisation – ID approval required. Patient with Non CF bronchiectasis as per guideline (Up to 14 days) Meningitis (48 hours) Community acquired sepsis (72 hours) CSF shunt infection (48 hours) Severe/ life threatening community acquired pneumonia (Up to 48 hours) Tracheitis/epiglottitis (24 hours) Mastoiditis (72 hours) Cholangitis (72 hours) Orbital cellulitis (48 hours) Hib unvaccinated – Septic arthritis, Osteomyelitis, Moderate to severe periorbital (48 hours) Suspected necrotising fasciitis (24 hours)	Amber
Cefoxitin (IV) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications for specific timeframes (for ongoing use, AMS code required): For Use in accordance with CHQ Paediatric Surgical Antibiotic Prophylaxis protocol for abdominal and biliary surgery (see guideline for duration) Pre-approved for first dose challenge by Paediatric Immunologist/Allergist. Ongoing use/ desensitisation – ID approval required.	Amber
Ceftazidime (IV) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Febrile neutropenia (Oncology) – see criteria in guideline (72 hours) Patients with Cystic fibrosis– see criteria in guideline (Up to 14 days) Patient with Non CF bronchiectasis – see criteria in guideline (Up to 14 days) Nosocomial sepsis – delayed type hypersensitivity (PICU) (72 hours) Pre-approved for first dose challenge by Paediatric Immunologist/Allergist. Ongoing use/ desensitisation – ID approval required.	Amber
Ceftazidime intravitreal injection Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Upon advice from Ophthalmology for Acute management of Open Globe Injuries (health.qld.gov.au) (1 dose)	Amber
Ceftriaxone (IV) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Patient with Non CF bronchiectasis as per guideline (Up to 14 days) Febrile non-neutropenia (72 hours) Meningitis (48 hours) Community acquired sepsis (72 hours) CSF shunt infection (48 hours) Severe/ life threatening community acquired pneumonia (Up to 48 hours) Tracheitis/epiglottitis (24 hours) Mastoiditis (72 hours) Cholangitis (72 hours) Orbital cellulitis (48 hours) Hib unvaccinated – Septic arthritis, Osteomyelitis, Moderate to severe periorbital (48 hours) Suspected necrotising fasciitis (24 hours) Pre-approved for first dose challenge by Paediatric Immunologist/Allergist. Ongoing use/ desensitisation – ID approval required.	Amber
Ceftriaxone (IV) (HITH) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications for specific timeframes (for ongoing use, AMS code required): HITH - Patients with Non CF bronchiectasis as per guideline (Up to 14 days, 1^st dose as inpatient) According to HITH ED pathway (1^st dose in ED, then up to 48 hours on HITH- ID review and AMS code required for ongoing treatment) for the following indications: Community acquired pneumonia (not tolerating oral therapy) Cellulitis Lymphadenitis Pre-septal/peri-orbital cellulitis	Amber
Cefuroxime (oral) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Pre-approved for first dose challenge by Paediatric Immunologist/Allergist. Ongoing use/ desensitisation – ID approval required. Patients with Non CF bronchiectasis as per guideline	Amber
Chloramphenicol eye ointment Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications: For Ophthalmic use only	Amber
Cephazolin (Cefazolin) Intravitreal and intracameral injection Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Upon advice from Ophthalmology for Acute management of Open Globe Injuries (health.qld.gov.au) (1 dose)	Amber
Ciprofloxacin (oral) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Patients with Cystic fibrosis– see criteria in guideline Patient with Non-CF bronchiectasis – see criteria in guideline Single dose as Chemoprophylaxis of meningococcal contacts on advice from Infectious diseases consultant/ Public health medical officer (according to CHQ Antibiocard) According to Acute management of Open Globe Injuries (health.qld.gov.au) guideline (5 days) Chemoprophylaxis of meningococcal contacts on advice from ID consultant (single dose) Pre-approved for first dose challenge by Paediatric Immunologist/Allergist. Ongoing use/ desensitisation – ID approval required.	Amber
Ciprofloxacin eardrops Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications: As per QH LAM criteria and CHQ Otitis Externa guideline	Amber
Ciprofloxacin/ Hydrocortisone (Ciproxin HC) eardrops Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications: As per QH LAM criteria for Deadly Ears ENT outreach service QCH use as per CHQ Patient group medication approval list indications	Amber
Clindamycin (IV) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications for specific timeframes (for ongoing use, AMS code required): In neonates only, for approved indications (sepsis with nmMRSA risk factors) (48 hours) Pre-approved for first dose challenge by Paediatric Immunologist/Allergist. Ongoing use/ desensitisation – ID approval required.	Amber
Clindamycin (oral) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Mild Cellulitis – nmMRSA risk factors (72 hours) Mild Periorbital cellulitis - nmMRSA risk factors (72 hours) Impetigo – nmMRSA risk factors (72 hours) Cervical lymphadenitis – nmMRSA risk factors (72 hours) Cystic fibrosis – outpatient MRSA eradication (14 days) Pre-approved for first dose challenge by Paediatric Immunologist/Allergist. Ongoing use/ desensitisation – ID approval required.	Amber
Colistin (inhaled) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Cystic fibrosis - according to eligibility criteria in guideline	Amber
Dapsone (oral) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Second line agent for PJP prophylaxis in oncology/haematology patients Pre-approved for first dose challenge by Paediatric Immunologist/Allergist. Ongoing use/ desensitisation – ID approval required.	Amber
Doxycycline (IV – SAS) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications: For single dose - use by Physicians trained in interventional radiology and with proper skills in sclerotherapy – for use in sclerotherapy for treatment of lymphatic malformations in paediatric patients.(SAS approval required)	Amber
Doxycycline (oral) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Acne (adolescents) (3 months under guidance of Dermatologist). Water immersed wound infection according to guideline criteria (Children over 8 years of age) (24 hours)	Amber
Erythromycin (IV, oral) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved: Pre-approved for first dose challenge by Paediatric Immunologist/Allergist. Ongoing use/ desensitisation – ID approval required.	Amber
Famciclovir (oral) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Pre-approved for first dose challenge by Paediatric Immunologist/Allergist. Ongoing use/ desensitisation – ID approval required. Herpes zoster in immunocompetent patients (72 hours) Herpes zoster in immunocompromised patients (72 hours) Ophthalmic herpes zoster (72 hours)	Amber
Fluconazole (IV/ oral) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications for specific timeframes (for ongoing use, AMS code required): For use in accordance with Oncology/ Haematology antifungal prophylaxis and treatment guideline. Pre-approved for first dose challenge, SPT or IDT by Paediatric Immunologist/Allergist. Ongoing use/ desensitisation – ID approval required.	Amber
Gentamicin (IV) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Neonatal sepsis (meningitis excluded) (48 hours) Neonatal community acquired pneumonia (48 hours) Community acquired sepsis (meningitis excluded) (48 hours) Urosepsis/ UTI/ Pyelonephritis (up to 48 hours) Febrile neutropenia – septic shock (24 hours) As per Surgical antibiotic prophylaxis guideline (single dose) Endocarditis (24 hours) Complicated appendicitis (up to 72 hours) Hospital-In-The-Home (HITH) Emergency/ ED pathways- Urinary tract infection/ Pyelonephritis (1^st dose in ED, up to 48 hours on HITH, then ID approval required) Pre-approved for first dose challenge, SPT or IDT by Paediatric Immunologist/Allergist. Ongoing use/ desensitisation – ID approval required.	Amber
Gentamicin eye drops Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications: Use upon advice from Ophthalmology team	Amber
Griseofulvin (oral) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications for specific timeframes (for ongoing use, AMS code required): For use in recalcitrant laboratory proven tinea infection according to the Australian Therapeutic guidelines (Antibiotic) Pre-approved for first dose challenge by Paediatric Immunologist/Allergist. Ongoing use/ desensitisation – ID approval required.	Amber
Hydroxychloroquine (oral) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications: For use according to the QH LAM by an authorised prescriber in accordance with the Medicines and Poisons (Medicines) Regulation 2021.	Amber
Itraconazole (oral) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Cystic fibrosis – Allergic bronchopulmonary aspergillosis (ABPA) (up to 3 months) For use in accordance with Oncology/ Haematology antifungal prophylaxis and treatment guideline. Pre-approved for first dose challenge by Paediatric Immunologist/Allergist. Ongoing use/ desensitisation – ID approval required.	Amber
Lincomycin (IV) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Community acquired sepsis, meningitis excluded, nmMRSA risk factors (48 hours) Empyema (48 hours) Severe / Life-threatening/ MRSA pneumonia (PICU) (24 hours) Immediate severe beta-lactam hypersensitivity according to indications listed in the CHQ Antibiocard (24 hours) Severe cervical lymphadenitis with nmMRSA risk factors (48 hours) Osteomyelitis with nmMRSA risk factors (48 hours) Septic Arthritis with nmMRSA risk factors (48 hours) Moderate to Severe Periorbital cellulitis with nmMRSA risk factors (48 hours) Severe Cellulitis with nmMRSA risk factors (48 hours) Suspected necrotising fasciitis (24 hours) For use in accordance with CHQ Surgical Antibiotic Prophylaxis guidelines, in patients who have an immediate severe type hypersensitivity to penicillins/ cephalosporins (single dose, ongoing use ID approval required) Pre-approved for first dose challenge by Paediatric Immunologist/Allergist. Ongoing use/ desensitisation – ID approval required.	Amber
Mebendazole (oral) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications: According to QH LAM indications and Australian Therapeutic guidelines (Antibiotic) Pre-approved for first dose challenge by Paediatric Immunologist/Allergist. Ongoing use/ desensitisation – ID approval required.	Amber
Minocycline (oral) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Acne (adolescents) upon advice from Dermatologist (up to 3 months) Pre-approved for first dose challenge by Paediatric Immunologist/Allergist. Ongoing use/ desensitisation – ID approval required.	Amber
Mupirocin (intranasal) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications for specific timeframes (for ongoing use, AMS code required): For use in according to CHQ Management of boils (furunculosis) (MSSA and MRSA decolonisation) OR for Eradication of Staph Aureus nasal colonisation in Cardiac surgery patients	Amber
Mupirocin (topical) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications: Prevention of peritoneal dialysis catheter exit site infection	Amber
Neomycin (oral) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. SAS approval required.	Red
Ofloxacin (eyedrops) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications: Use upon advice from ophthalmology team.	Amber
Oseltamivir (oral) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications: For use according to Queensland Infection Clinical Network Guidelines for prescribing oseltamivir for seasonal influenza in 2022	Amber
Piperacillin/Tazobactam (IV) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Febrile neutropenia (72 hours) Cystic fibrosis – see guideline (Up to 14 days – inpatient/HITH) Non CF bronchiectasis – as per guideline eligibility criteria (Up to 14 days – inpatient only, HITH – ID approval required) Complicated appendicitis (Up to 7 days) Peritonitis (72 hours) Necrotising enterocolitis (72 hours) Compound fractures (24 hours) Surgical antibiotic prophylaxis – Liver and renal transplantation (Up to 24 hours) Surgical antibiotic prophylaxis - Percutaneous cholangiogram and Burns (contaminated wound) (1 dose) Fever in patient with CVAD in-situ according to eligibility criteria (Up to 48 hours) Pre-approved for first dose challenge by Paediatric Immunologist/Allergist. Ongoing use/ desensitisation – ID approval required.	Amber
Posaconazole (oral) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications: Antimould prophylaxis as per Oncology/ Haematology antifungal prophylaxis and treatment guideline criteria. (Treatment – ID approval required) Pre-approved for first dose challenge by Paediatric Immunologist/Allergist. Ongoing use/ desensitisation – ID approval required.	Amber
Rifampicin (oral) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Chemoprophylaxis of meningococcal contacts on advice from ID consultant (48 hours) Pre-approved for first dose challenge by Paediatric Immunologist/Allergist. Ongoing use/ desensitisation – ID approval required.	Amber
Teicoplanin (IV) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Single dose according to eligibility criteria in CHQ-PROC-03455 Management of Compromised Central Venous Access Device (CVAD) Post cardiac surgery (within 72 hours of surgery) suspicion of infection WITHOUT a focus (24 hours) Deep cardiac surgical wound infection (mediastinitis suspected) (24 hours) Cardiac patient with CVAD associated or bloodstream infection focus (24 hours) Nosocomial sepsis (Hospital-acquired and healthcare associated sepsis) (48 hours) Pre-approved for first dose challenge by Paediatric Immunologist/Allergist. Ongoing use/ desensitisation – ID approval required.	Amber
Terbinafine (topical) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or use outside of pre-approved indications as listed below. Pre-approved indications: For use according to QH LAM criteria	Amber
Terbinafine (oral) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications: Upon advice from Dermatologist for microbiologically proven chronic onychomycosis or extensive tinea unresponsive to griseofulvin or in patients intolerant of griseofulvin according to Australian Therapeutic guidelines (Antibiotic) and QH LAM criteria Pre-approved for first dose challenge by Paediatric Immunologist/Allergist. Ongoing use/ desensitisation – ID approval required.	Amber
Tobramycin (IV/ inhaled/ nebulised) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Cystic fibrosis – as per guideline criteria (IV therapy – up to 14 days, inhaled/nebulised – see guideline) Non CF bronchiectasis (IV – inpatient up to 14 days, HITH - ID approval required) Non CF bronchiectasis (inhaled/nebulised – QCH use endorsed as per guideline; Other sites – as per local ID approval practices)	Amber
Tobramycin (eyedrops and eye ointment) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or use outside of pre-approved indications as listed below. Pre-approved indications: Upon ophthalmologist advice.	Amber
Trimethoprim/ sulfamethoxazole (IV) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Initial treatment of PJP pneumonia where oral therapy is not tolerated (Up to 48 hours, ID consult and approval for ongoing use required) Pre-approved for first dose challenge by Paediatric Immunologist/Allergist. Ongoing use/ desensitisation – ID approval required.	Amber
Valaciclovir (oral) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Prophylaxis of viral infection for 12 months following allogeneic bone marrow transplant Prophylaxis of viral infection for 3 months following autologous bone marrow transplant. Cutaneous or mucosal herpes simplex in immunosuppressed patients (72 hours) Herpes zoster in immunocompromised patients (72 hours) Ophthalmic herpes zoster (72 hours) Pre-approved for first dose challenge by Paediatric Immunologist/Allergist. Ongoing use/ desensitisation – ID approval required.	Amber
ValGANciclovir (oral) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications for specific timeframes (for ongoing use, AMS code required): For use as CMV prophylaxis only in accordance with the CHQ Liver transplant protocol and CHQ Renal transplant protocol ID consult and approval required for prophylaxis in other transplant cohorts and for CMV Treatment	Amber
Vancomycin (IV) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Penetrating eye injuries/ open globe injuries as per guideline (48 hours) Febrile neutropenia – AML, CVAD associated fever, septic shock (48 hours) Single dose according to eligibility criteria in CHQ-PROC-03455 Management of Compromised Central Venous Access Device (CVAD) Peri-operative MRSA cover per Surgical antibiotic prophylaxis guideline (1 dose) Meningitis (24 hours) Community acquired sepsis (48 hours) CSF shunt infection (48 hours) Severe/ life threatening community acquired pneumonia (Up to 48 hours) Endocarditis (24 hours) Pre-approved for first dose challenge by Paediatric Immunologist/Allergist. Ongoing use/ desensitisation – ID approval required.	Amber
Vancomycin (intravitreal or intracameral injection) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or use outside of pre-approved indications as listed below. Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Upon advice from Ophthalmology for Acute management of Open Globe Injuries (health.qld.gov.au) (1 dose)	Amber
Voriconazole (intravitreal or intracameral injection) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or use outside of pre-approved indications as listed below. Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Upon advice from Ophthalmology for Acute management of Open Globe Injuries (health.qld.gov.au) (1 dose)	Amber
Abacavir (oral) ID consult and approval required. For non LAM use Individual Patient Approval (CGOV IPA) approved by ID SMO required.	Red
Adefovir (oral) ID consult and approval required. For non LAM use Individual Patient Approval (CGOV IPA) approved by ID SMO required.	Red
Amikacin (IV and nebulised) ID consult and approval required. For non LAM use Individual Patient Approval (CGOV IPA) approved by ID SMO required.	Red
Amorolfine (topical solution) ID consult and approval required. For non LAM use Individual Patient Approval (CGOV IPA) approved by ID SMO required.	Red
Amphotericin B lipid complex (Abelcet) (SAS) (IV) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) · Custom Portal (health.gov.au) approval required	Red
Amphotericin (Fungizone) (SAS) (IV) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) · Custom Portal (health.gov.au) approval required	Red
Anidulafungin (IV) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Artemeter/lumefantrine (Riamet) (oral) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Artesunate (SAS) (IV) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) · Custom Portal (health.gov.au) approval required	Red
Atazanavir (oral) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Atovaquone (oral) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Atovaquone/ Proguanil (oral) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Aztreonam IV and nebulised (SAS) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Nebulised: Special Access Scheme (SAS) · Custom Portal (health.gov.au) approval required	Red
Bacitracin (topical) (SAS) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) · Custom Portal (health.gov.au) approval required	Red
Bedaquiline (oral) (SAS) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) · Custom Portal (health.gov.au) approval required	Red
Benznidazole (oral) (SAS) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) · Custom Portal (health.gov.au) approval required	Red
Brincidofovir (compassionate access) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use CHQMAC approval required	Red
Capreomycin (IV) (SAS) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) · Custom Portal (health.gov.au) approval required	Red
Casirivimab/Imdevimab (Ronapreve) ID consult and approval required for use within CHQ as per the criteria for access from the National Medical Stockpile. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Tixagevimab/Cilgavimab (Evusheld) ID consult and approval required for use within CHQ as per the criteria for access from the National Medical Stockpile. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Caspofungin (IV) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Cefpodoxime (oral) (SAS) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) · Custom Portal (health.gov.au) approval required	Red
Ceftolozane/tazobactam (IV) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Ceftazidime/avibactam (IV) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Chloramphenicol (IV) (SAS) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) · Custom Portal (health.gov.au) approval required	Red
Chloroquine (SAS) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) · Custom Portal (health.gov.au) approval required	Red
Cidofovir (IV) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Ciprofloxacin (IV) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Water immersed wound infection - Prophylaxis for DEEP tissue injury (e.g. bones, joint or tendons) OR Empiric IV treatment of established infection (Up to 24 hours) Penetrating eye injuries/ open globe injuries as per guideline (48 hours) Alternative for immediate severe type hypersensitivity as outlined in CHQ Antibiocard (24 hours)	Red
Clofazimine (oral) (SAS) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) · Custom Portal (health.gov.au) approval required	Red
Colistin (IV) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Clarithromycin (oral) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Cycloserine (oral) (SAS) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) · Custom Portal (health.gov.au) approval required	Red
Daclatasvir (oral) (SAS) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) · Custom Portal (health.gov.au) approval required	Red
Daptomycin (IV) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Darunavir (oral) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Delamanid (oral) (SAS) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) · Custom Portal (health.gov.au) approval required	Red
Dolutegravir (oral) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Compassionate use - CHQMAC approval required	Red
Doripenem (IV) (SAS) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) · Custom Portal (health.gov.au) approval required	Red
Efavirenz (oral) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Elvitegravir (oral) (as part of FDC product) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Emtricitabine (oral) (as part of FDC product) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Enfuviritide (oral) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Entecavir (oral) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Ethambutol (oral) (IV – SAS) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) · Custom Portal (health.gov.au) approval required	Red
Ertapenem (IV) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Erythromycin (IV) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Ethionamide (oral) (SAS) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) · Custom Portal (health.gov.au) approval required 3>	Red
Fidaxomicin (oral) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Flucytosine (IV/ oral) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) · Custom Portal (health.gov.au) approval required	Red
Fosfomycin oral and IV (SAS) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use IV formulation: Special Access Scheme (SAS) · Custom Portal (health.gov.au) approval required	Red
Foscarnet (IV) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Fusidic acid (Sodium fusidate) (oral) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Oral suspension: Special Access Scheme (SAS) · Custom Portal (health.gov.au) approval required	Red
Ganciclovir (IV) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Imipenem/cilastatin (IV) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Isavuconazole (IV/oral) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Isoniazid oral and IV (SAS) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use IV formulation: Special Access Scheme (SAS) · Custom Portal (health.gov.au) approval required	Red
Ivermectin (oral) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Ketoconazole (oral/ shampoo) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Lamivudine (oral) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Ledipasvir with Sofosbuvir (oral) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Letermovir (IV/ oral) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Levofloxacin (IV/ oral) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) · Custom Portal (health.gov.au) approval required	Red
Linezolid (IV/ oral) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Lopinavir/Ritonavir (oral) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Nirmatrelvir/ Ritonavir (Paxlovid) (oral) ID consult and approval required for use within CHQ as per the criteria for access from the National Medical Stockpile. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Molnupiravir (oral) ID consult and approval required for use within CHQ as per the criteria for access from the National Medical Stockpile. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Sotrovimab (IV) ID consult and approval required for use within CHQ as per the criteria for access from the National Medical Stockpile. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Maraviroc (oral) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Mefloquine (oral) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Miltefosine (oral) (SAS) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) · Custom Portal (health.gov.au) approval required	Red
Moxifloxacin (IV/ oral) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Meropenem/Vaborbactam (IV) (SAS) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) · Custom Portal (health.gov.au) approval required	Red
Meropenem (IV) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications for specific timeframes (for ongoing use, AMS code required): Febrile neutropenia and as peri-operative prophylaxis for Liver transplantation / Renal transplantation– patients with immediate severe hypersensitivity to penicillins/cephalosporins (Up to 24 hours) External wound or inoculation with Suspected necrotising fasciitis (Up to 24 hours)	Red
Methenamine Hippurate (oral) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Micafungin (IV) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications for specific timeframes (for ongoing use, AMS code required): For use in accordance with Oncology/ Haematology antifungal prophylaxis and treatment guideline. Pre-approved for first dose challenge, SPT or IDT by Paediatric Immunologist/Allergist. Ongoing use/ desensitisation – ID approval required	Amber
Nalidixic acid (PO) (SAS) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) · Custom Portal (health.gov.au) approval required	Red
Natamycin eyedrops (SAS) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) · Custom Portal (health.gov.au) approval required	Red
Netilmicin (SAS) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) · Custom Portal (health.gov.au) approval required	Red
Nevirapine (oral) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Niclosamide (oral) (SAS) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) · Custom Portal (health.gov.au) approval required	Red
Nitazoxanide (oral) (SAS) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) · Custom Portal (health.gov.au) approval required	Red
Norfloxacin (oral) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Palivizumab (IM) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications for specific timeframes (for ongoing use, AMS code required): For use in accordance with CHQ-GDL-01071 Palivizumab for Respiratory Syncytial Virus (RSV) prophylaxis in high risk paediatric patients	Red
Paromomycin (oral and topical – SAS) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) · Custom Portal (health.gov.au) approval required	Red
Para-Aminosalicylic acid (SAS) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) · Custom Portal (health.gov.au) approval required	Red
Pentamidine (IV and nebulised) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Peramivir (IV) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Pivmecillinam (oral) (SAS) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) · Custom Portal (health.gov.au) approval required	Red
Pentamidine (IV and nebulised) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Polymyxin B (SAS) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) · Custom Portal (health.gov.au) approval required	Red
Posaconazole (IV) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Praziquantel (oral) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Pretomanid (oral) (SAS) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) · Custom Portal (health.gov.au) approval required	Red
Primaquine (oral) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Pristinamycin (oral) (SAS) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) · Custom Portal (health.gov.au) approval required	Red
Pylera ( Bismuth, Metronidazole, Tetracycline) (SAS) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) · Custom Portal (health.gov.au) approval required	Red
Pyrazinamide (oral) (SAS) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) · Custom Portal (health.gov.au) approval required	Red
Pyrimethamine (oral) (SAS) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) · Custom Portal (health.gov.au) approval required	Red
Quinine (IV/ oral) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Quinupristin/Dalfopristin (IV) (SAS) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) · Custom Portal (health.gov.au) approval required	Red
Raltegravir (oral) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use 100mg tablets: Special Access Scheme (SAS) · Custom Portal (health.gov.au) approval required	Red
Remdesivir (IV) ID consult and approval required for use within CHQ as per the criteria for access from the National Medical Stockpile. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Ribavirin (oral) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Rifabutin (oral) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Rifampicin (IV) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Rifapentine (oral) (SAS) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) · Custom Portal (health.gov.au) approval required	Red
Rifaximin (oral) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Suspension: Special Access Scheme (SAS) · Custom Portal (health.gov.au) approval required	Red
Rilpirivine (with tenofovir and emtricitabine) (oral) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Sarilumab ID consult and approval required for use within CHQ as per the criteria for access from the National Medical Stockpile. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Sofosbuvir ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Streptomycin (IM) (SAS) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) · Custom Portal (health.gov.au) approval required	Red
Sulfadiazine (oral) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Tafenoquine (oral) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Taurolidine/citrate antiseptic lock (Taurolock) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Tedizolid (SAS) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) · Custom Portal (health.gov.au) approval required	Red
Telithromycin (SAS) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) · Custom Portal (health.gov.au) approval required	Red
Tenofovir ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Tetracycline (SAS) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) · Custom Portal (health.gov.au) approval required	Red
Ticarcillin/clavulanate - Drug discontinued in 2018	Red
Triclosan skin wash ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Tigecycline (IV) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Vancomycin (oral) Approval required: Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use or AMS code for use outside of pre-approved indications as listed below. Pre-approved indications for specific timeframes (for ongoing use, AMS code required): For use in accordance with Paediatric Clostridium (Clostridioides) Difficile Infection - Treatment Guidelines Oral mixture: Special Access Scheme (SAS) · Custom Portal (health.gov.au) approval required	Red
Voriconazole (IV and eyedrops) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Zanamavir (inhaled) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use	Red
Zidovudine oral and IV (SAS) ID consult and approval required. Individual Patient Approval (CGOV IPA) approved by ID required for all non LAM use Special Access Scheme (SAS) · Custom Portal (health.gov.au) approval required	Red

Children’s Health Queensland

Queensland Children’s Hospital

Research

Children’s Health Queensland

Queensland Children’s Hospital

Research and education

Antimicrobial restrictions

Antimicrobial restrictions

Antimicrobial formulary

Use of a restricted antimicrobials at QCH can be authorised with a unique AMS Code by the Paediatric Infection Specialists/clinicians listed below

QCH Antimicrobial Formulary

The QCH Antimicrobial formulary is divided into the following three categories:

Unrestricted (green)

Restricted (amber)

Reserved (red)

Search QCH Antimicrobial formulary (generic name)

Amoxicillin (oral/IV)

Amoxicillin / Clavulanic acid (oral)

Amphotericin B lozenges (oral)

Benzathine penicillin (IM)

Benzylpenicillin (IV)

Cefaclor (oral)

Cefalexin (oral)

Cefazolin (IV) (inpatient)

Chloramphenicol eyedrops (topical)

Clotrimazole (topical)

Dicloxacillin (IV/oral)

Flucloxacillin (IV/oral)

Framycetin - Gramicidin - Dexamethasone (Sofradex / Otodex) Ear drops

Metronidazole (oral/IV)

Miconazole (topical)

Nitrofurantoin (oral capsules)

Nystatin (oral/ topical)

Permethrin (topical)

Phenoxymethylpenicillin (oral)

Pyrantel (oral)

Roxithromycin (150mg oral tablets)

Tinidazole (oral) (SAS)

Trimethoprim (oral tablets)

Trimethoprim / Sulfamethoxazole (oral)

Aciclovir (eye ointment)

Aciclovir (topical cream)

Aciclovir (IV/oral)

Albendazole (oral)

Amoxicillin/Clavulanate (IV)

Amoxicillin, Clarithromycin and Esomeprazole (Triple therapy)

Liposomal Amphotericin B (IV)

Azithromycin (IV)

Azithromycin (oral)

Cefazolin (with preservative) eyedrops

Cefazolin (IV) (HITH)

Cefepime (IV)

Cefotaxime (IV)

Cefoxitin (IV)

Ceftazidime (IV)

Ceftazidime intravitreal injection

Ceftriaxone (IV)

Ceftriaxone (IV) (HITH)

Cefuroxime (oral)

Chloramphenicol eye ointment

Cephazolin (Cefazolin) Intravitreal and intracameral injection

Ciprofloxacin (oral)

Ciprofloxacin eardrops

Ciprofloxacin/ Hydrocortisone (Ciproxin HC) eardrops

Clindamycin (IV)

Clindamycin (oral)

Colistin (inhaled)

Dapsone (oral)

Doxycycline (IV – SAS)

Doxycycline (oral)

Erythromycin (IV, oral)

Famciclovir (oral)

Fluconazole (IV/ oral)

Gentamicin (IV)

Gentamicin eye drops

Griseofulvin (oral)

Hydroxychloroquine (oral)

Itraconazole (oral)

Lincomycin (IV)

Mebendazole (oral)